葛蘭素史克 GSK 深 滬
等待開盤 08-08 09:30:00 美东时间
37.61
+0.860
+2.34%
華盛通- 最 高37.625
- 今 開37.14
- 成交量 135.07万股
- 最 低 37.07
- 昨 收 36.75
- 總市值 759.35亿
- 52周最高 43.4733
- 市盈率 靜 23.66
- 換手率 0.00%
- 52周最低 30.8877
- 委 比 24.24%
- 總股本 20.19亿
- 歷史最高 44.5171
- 量 比 0.72
- 振 幅 1.51%
- 歷史最低 10.2953
- 每 手 1
- 風險率 2.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GSK’s RSV Vaccine Study: Key Insights for Investors
GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)) announced an upd...
11分钟前
GSK Completes Promising Study on Gonorrhea Vaccine
GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)) announced an upd...
14分钟前
What Does the Market Think About GSK?
GSK's (NYSE:GSK) short percent of float has fallen 27.17% since its last report...
08-07 23:00
ETF市场日报 | 稀土板块集体领涨！创新药相关ETF连续回调
2025年8月7日，Wind数据显示，A股三大指数今日涨跌不一，沪指创今年以来新高。截止收盘，沪指涨0.16%；深证成指跌0.18%；创业板指跌0.68%。沪深...
08-07 15:22
Actuate Therapeutics Initiates Phase 1b Trial Of Elraglusib In Combination With Incyte's PD-1 Inhibitor, Retifanlimab, And Modified FOLFIRINOX As Frontline Therapy In Advanced Pancreatic Adenocarcinoma
Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU)
08-06 20:47
前7月九成普通股基上涨 华安医药生物股票涨幅翻倍
中国经济网北京8月6日讯 （记者 康博） 截至7月31日收盘，在今年前7月的983只（各份额分开计算，下同）普通股票型基金中，业绩上涨的共有905只，占比高达...
08-06 15:28
赛诺菲回复：波立达确已退出中国市场
（来源：中国食品药品网） 中国食品药品网讯（记者李易真） 近日，一份《关于波立达®（阿利西尤单抗注射液）的告知函》（以下简称《告知函》）在医药行业内流传，引...
08-06 15:03
默沙东与康方分手MK-1308！CTLA-4靶点彻底凉凉了吗？
（来源：求实药社） 7月29日，默沙东在其第二季度项目进展更新中，首次公开披露了多项关键研发项目的终止决策。这一系列调整，是其正在推进的成本控制和资源重配策略的...
08-06 12:07
赛诺菲波立达突然停供中国，跨国药企撤离潮背后的“腾笼换鸟”
（来源：医趋势） 7月1日，一封关于“波立达(阿利西尤单抗注射液)的告知函”在业界流传。8月4日，赛诺菲向媒体确认，长效降脂药阿利西尤单抗在中国已停供。此事早...
08-06 10:39
公司簡介
公司名稱
|
葛兰素史克
|
行業分類
|
制药
|
業務描述
|
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
|
GSK’s RSV Vaccine Study: Key Insights for Investors
GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)) announced an upd...
11分钟前
GSK Completes Promising Study on Gonorrhea Vaccine
GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)) announced an upd...
14分钟前
What Does the Market Think About GSK?
GSK's (NYSE:GSK) short percent of float has fallen 27.17% since its last report...
08-07 23:00
ETF市场日报 | 稀土板块集体领涨！创新药相关ETF连续回调
2025年8月7日，Wind数据显示，A股三大指数今日涨跌不一，沪指创今年以来新高。截止收盘，沪指涨0.16%；深证成指跌0.18%；创业板指跌0.68%。沪深...
08-07 15:22
Actuate Therapeutics Initiates Phase 1b Trial Of Elraglusib In Combination With Incyte's PD-1 Inhibitor, Retifanlimab, And Modified FOLFIRINOX As Frontline Therapy In Advanced Pancreatic Adenocarcinoma
Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU)
08-06 20:47
前7月九成普通股基上涨 华安医药生物股票涨幅翻倍
中国经济网北京8月6日讯 （记者 康博） 截至7月31日收盘，在今年前7月的983只（各份额分开计算，下同）普通股票型基金中，业绩上涨的共有905只，占比高达...
08-06 15:28
赛诺菲回复：波立达确已退出中国市场
（来源：中国食品药品网） 中国食品药品网讯（记者李易真） 近日，一份《关于波立达®（阿利西尤单抗注射液）的告知函》（以下简称《告知函》）在医药行业内流传，引...
08-06 15:03
默沙东与康方分手MK-1308！CTLA-4靶点彻底凉凉了吗？
（来源：求实药社） 7月29日，默沙东在其第二季度项目进展更新中，首次公开披露了多项关键研发项目的终止决策。这一系列调整，是其正在推进的成本控制和资源重配策略的...
08-06 12:07
赛诺菲波立达突然停供中国，跨国药企撤离潮背后的“腾笼换鸟”
（来源：医趋势） 7月1日，一封关于“波立达(阿利西尤单抗注射液)的告知函”在业界流传。8月4日，赛诺菲向媒体确认，长效降脂药阿利西尤单抗在中国已停供。此事早...
08-06 10:39
派息除權日
|
每股總股息
| 派息日期 |
2025-08-15
|
0.42
|
2025-10-09
|
2025-05-16
|
0.42
|
2025-07-10
|
2025-02-21
|
0.39
|
2025-04-10
|
2024-11-15
|
0.38
|
2025-01-09
|
2024-08-16
|
0.38
|
2024-10-10
|
2024-05-16
|
0.37
|
2024-07-11
|
2024-02-22
|
0.40
|
2024-04-11
|
2023-11-16
|
0.33
|
2024-01-11
|
2023-08-17
|
0.35
|
2023-10-12
|
2023-05-18
|
0.34
|
2023-07-13
|
2023-02-23
|
0.33
|
2023-04-13
|
2022-11-17
|
0.31
|
2023-01-12
|
2022-08-18
|
0.38
|
2022-10-06
|
2022-05-19
|
0.34
|
2022-07-01
|
2022-02-24
|
0.61
|
2022-04-07
|
2021-11-18
|
0.52
|
2022-01-13
|
2021-08-19
|
0.52
|
2021-10-07
|
2021-05-20
|
0.52
|
2021-07-08
|
2021-02-18
|
0.62
|
2021-04-08
|
2020-11-12
|
0.49
|
2021-01-14
|
2020-08-13
|
0.48
|
2020-10-08
|
2020-05-14
|
0.46
|
2020-07-09
|
2020-02-20
|
0.59
|
2020-04-09
|
2019-11-14
|
0.48
|
2020-01-09
|
2019-08-08
|
0.46
|
2019-10-10
|
2019-05-16
|
0.47
|
2019-07-11
|
2019-02-21
|
0.59
|
2019-04-11
|
2018-11-15
|
0.48
|
2019-01-10
|
2018-08-09
|
0.49
|
2018-10-11
|
2018-05-10
|
0.50
|
2018-07-12
|
2018-02-22
|
0.65
|
2018-04-12
|
2017-11-09
|
0.51
|
2018-01-11
|
2017-08-09
|
0.50
|
2017-10-12
|
2017-05-10
|
0.49
|
2017-07-13
|
2017-02-22
|
0.57
|
2017-04-13
|
2016-11-02
|
0.46
|
2017-01-12
|
2016-08-10
|
0.46
|
2016-10-13
|
2016-05-11
|
0.50
|
2016-07-14
|
2016-02-17
|
1.22
|
2016-04-14
|
2015-11-10
|
0.54
|
2016-01-14
|
2015-08-12
|
0.57
|
2015-10-01
|
2015-05-13
|
0.58
|
2015-07-09
|
2015-02-18
|
0.70
|
2015-04-09
|
2014-11-05
|
0.61
|
2015-01-08
|
2014-08-06
|
0.65
|
2014-10-02
|
2014-05-14
|
0.64
|
2014-07-10
|
2014-02-19
|
0.75
|
2014-04-10
|
2013-11-13
|
0.62
|
2014-01-09
|
2013-08-07
|
0.55
|
2013-10-03
|
2013-05-08
|
0.55
|
2013-07-11
|
2013-02-20
|
0.69
|
2013-04-11
|
2012-11-14
|
0.58
|
2013-01-03
|
2012-08-08
|
0.53
|
2012-10-04
|
2012-05-09
|
0.55
|
2012-07-05
|
2012-02-15
|
0.82
|
2012-04-12
|
2011-11-02
|
0.54
|
2012-01-05
|
2011-08-03
|
0.52
|
2011-10-06
|
2011-05-04
|
0.53
|
2011-07-07
|
2011-02-09
|
0.62
|
2011-04-07
|
2010-10-27
|
0.51
|
2011-01-06
|
2010-07-28
|
0.46
|
2010-10-07
|
2010-05-05
|
0.46
|
2010-07-08
|
2010-02-10
|
0.57
|
2010-04-08
|
2009-11-04
|
0.49
|
2010-01-07
|
2009-07-29
|
0.46
|
2009-10-08
|
2009-04-29
|
0.41
|
2009-07-09
|
2009-02-11
|
0.49
|
2009-04-09
|
2008-10-29
|
0.47
|
2009-01-08
|
2008-07-30
|
0.52
|
2008-10-09
|
2008-04-30
|
0.52
|
2008-07-10
|
2008-02-13
|
0.63
|
2008-04-10
|
2007-10-31
|
0.53
|
2008-01-10
|
2007-08-01
|
0.49
|
2007-10-11
|
2007-05-02
|
0.48
|
2007-07-12
|
2007-02-14
|
0.55
|
2007-04-12
|
2006-11-01
|
0.45
|
2007-01-04
|
2006-08-02
|
0.41
|
2006-10-05
|
2006-05-10
|
0.39
|
2006-07-06
|
2006-02-15
|
0.49
|
2006-04-06
|
2005-11-02
|
0.36
|
2006-01-05
|
2005-08-03
|
0.35
|
2005-10-06
|
2005-05-11
|
0.38
|
2005-07-07
|
2005-02-16
|
0.44
|
2005-04-07
|
2004-11-03
|
0.37
|
2005-01-06
|
2004-08-04
|
0.37
|
2004-09-30
|
2004-05-12
|
0.35
|
2004-07-01
|
2004-02-18
|
0.52
|
2004-04-15
|
2003-10-29
|
0.30
|
2004-01-06
|
2003-07-30
|
0.29
|
2003-10-02
|
2003-05-07
|
0.29
|
2003-07-03
|
2003-02-19
|
0.42
|
2003-04-17
|
2002-10-30
|
0.28
|
2003-01-03
|
2002-07-31
|
0.28
|
2002-10-03
|
2002-05-01
|
0.26
|
2002-07-05
|
2002-02-20
|
0.34
|
2002-04-18
|
2001-10-31
|
0.26
|
2002-01-03
|
2001-08-01
|
0.25
|
2001-10-04
|
2001-05-02
|
0.26
|
2001-07-05
|
2000-12-27
|
0.66
|
2001-04-27
|
2000-08-09
|
0.43
|
2000-10-26
|
2000-03-01
|
0.65
|
2000-06-05
|
1999-08-11
|
0.49
|
1999-10-12
|
1999-03-03
|
0.68
|
1999-06-01
|
1998-08-12
|
0.51
|
1998-10-13
|
1998-03-04
|
0.65
|
1998-06-01
|
1997-08-13
|
0.48
|
1997-10-13
|
1997-03-19
|
0.50
|
1997-05-30
|
1996-08-16
|
0.50
|
1996-10-11
|
1996-03-22
|
0.48
|
1996-05-30
|
1995-09-22
|
0.67
|
1995-11-02
|
1995-02-24
|
0.34
|
1995-04-20
|
1994-09-23
|
0.60
|
1994-12-01
|
1994-03-14
|
0.28
|
1994-04-21
|
1993-09-24
|
0.47
|
1993-11-29
|
1993-03-05
|
0.23
|
1993-05-10
|
1992-09-21
|
0.38
|
1992-11-23
|
1992-02-28
|
0.24
|
1992-05-11
|
1982-05-12
|
0.09
|
1982-07-06
|
1981-11-20
|
0.16
|
1982-01-19
|
1981-05-18
|
0.08
|
1981-07-03
|
1980-11-21
|
0.17
|
1981-01-19
|
